Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
$8.45
-7.3%
$15.72
$7.87
▼
$30.99
$561.00M-0.33773,932 shs465,680 shs
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
$7.93
-2.5%
$9.33
$7.72
▼
$14.39
$286.57M0.26148,453 shs219,368 shs
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
$8.80
-3.6%
$14.41
$8.41
▼
$25.59
$792.25M0.481.89 million shs1.36 million shs
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
$20.12
+2.0%
$21.30
$18.25
▼
$40.65
$1.39B0.65880,223 shs239,532 shs
Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
-2.77%-9.79%-50.30%-61.84%-39.92%
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
-1.57%-10.45%-9.96%-39.61%-37.86%
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
+6.66%-4.30%-31.09%-53.54%-45.36%
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
+0.61%-0.15%-3.62%-24.26%+18.71%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
$8.45
-7.3%
$15.72
$7.87
▼
$30.99
$561.00M-0.33773,932 shs465,680 shs
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
$7.93
-2.5%
$9.33
$7.72
▼
$14.39
$286.57M0.26148,453 shs219,368 shs
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
$8.80
-3.6%
$14.41
$8.41
▼
$25.59
$792.25M0.481.89 million shs1.36 million shs
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
$20.12
+2.0%
$21.30
$18.25
▼
$40.65
$1.39B0.65880,223 shs239,532 shs
Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
-2.77%-9.79%-50.30%-61.84%-39.92%
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
-1.57%-10.45%-9.96%-39.61%-37.86%
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
+6.66%-4.30%-31.09%-53.54%-45.36%
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
+0.61%-0.15%-3.62%-24.26%+18.71%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
2.72
Moderate Buy$30.33258.97% Upside
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
2.70
Moderate Buy$21.85175.45% Upside
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
2.82
Moderate Buy$41.40370.45% Upside
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
2.93
Moderate Buy$47.50136.14% Upside

Current Analyst Ratings Breakdown

Latest BNTC, SNDX, BCAX, and TYRA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/20/2026
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
Lower Price TargetBuy$33.00 ➝ $31.00
11/20/2026
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
Initiated CoverageBuy$54.00 ➝ $55.00
11/16/2026
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
Boost Price TargetOutperform$18.00 ➝ $18.27
11/16/2026
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
Boost Price TargetOutperform$17.00 ➝ $20.00
11/11/2026
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
Lower Price TargetBuy$42.00 ➝ $36.00
11/11/2026
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
Boost Price TargetOutperform$53.00 ➝ $57.00
11/11/2026
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
Lower Price TargetBuy$29.00 ➝ $27.00
11/10/2026
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
Reiterated RatingMarket Outperform
11/10/2026
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
Lower Price TargetOverweight$41.00 ➝ $30.00
11/10/2026
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
Lower Price TargetBuy$45.00 ➝ $43.00
11/10/2026
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
Lower Price TargetBuy$39.00 ➝ $37.00
(Data available from 11/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
N/AN/AN/AN/A$6.17 per shareN/A
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
N/AN/AN/AN/A$4.70 per shareN/A
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
$289.68M2.73N/AN/A($0.19) per share-46.32
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
N/AN/AN/AN/A$10.03 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
-$137.95M-$3.47N/AN/AN/AN/A-49.13%-45.01%N/A
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
-$45.55M-$1.02N/AN/AN/AN/A-27.60%-26.78%N/A
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
-$285.42M-$2.36N/AN/AN/A-72.32%-804.38%-34.93%N/A
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
-$119.95M-$2.64N/AN/AN/AN/A-40.12%-37.62%N/A

Latest BNTC, SNDX, BCAX, and TYRA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/13/2026Q3 2026
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
-$0.2750-$0.26+$0.0150-$0.26N/AN/A
11/10/2026Q3 2026
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
-$0.6687-$0.74-$0.0713-$0.74N/AN/A
11/9/2026Q3 2026
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
-$0.82-$1.04-$0.22-$1.04N/AN/A
11/2/2026Q3 2026
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
-$0.5041-$0.55-$0.0459-$0.55$81.38 million$83.30 million
9/14/2026Q4 2026
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
-$0.2643-$0.26+$0.0043-$0.2590$13.70 millionN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
N/AN/AN/AN/AN/A
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
N/AN/AN/AN/AN/A
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
N/AN/AN/AN/AN/A
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
N/A
8.81
8.81
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
N/A
19.62
34.00
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
38.95
4.69
4.37
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
N/A
23.93
23.93

Institutional Ownership

CompanyInstitutional Ownership
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
N/A
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
52.19%
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
N/A
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
84.14%

Insider Ownership

CompanyInsider Ownership
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
13.80%
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
7.96%
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
4.80%
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
12.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
10366.39 million57.23 millionOptionable
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
2436.12 million33.24 millionOptionable
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
29890.03 million85.71 millionOptionable
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
8769.08 million60.45 millionOptionable

Recent News About These Companies

HC Wainwright Cuts Earnings Estimates for Tyra Biosciences
How Tyra Biosciences Inc. (TYRA) Affects Rotational Strategy Timing
Tyra Biosciences (NASDAQ:TYRA) Price Target Raised to $57.00
Tyra Biosciences' Q3 Net Loss Widens

New MarketBeat Followers Over Time

Media Sentiment Over Time

Bicara Therapeutics stock logo

Bicara Therapeutics NASDAQ:BCAX

$8.45 -0.67 (-7.35%)
Closing price 03:58 PM Eastern
Extended Trading
$8.44 0.00 (-0.06%)
As of 04:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.

Benitec Biopharma stock logo

Benitec Biopharma NASDAQ:BNTC

$7.93 -0.21 (-2.53%)
Closing price 03:59 PM Eastern
Extended Trading
$7.92 -0.02 (-0.24%)
As of 04:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.

Syndax Pharmaceuticals stock logo

Syndax Pharmaceuticals NASDAQ:SNDX

$8.80 -0.33 (-3.61%)
As of 03:45 PM Eastern

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.

Tyra Biosciences stock logo

Tyra Biosciences NASDAQ:TYRA

$20.11 +0.39 (+1.95%)
Closing price 03:58 PM Eastern
Extended Trading
$20.09 -0.02 (-0.12%)
As of 04:02 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in Phase 1/2 clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in Phase 1 clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California.